This series of deleterious events interrupts the pathophysiological process resulting in an acute coronary disease. Landmark trials also have established aspirin, and also the inclusion of clopidogrel to aspirin, also because key curative agents at the context of severe coronary syndrome along with percutaneous coronary intervention. Double antiplatelet therapy has become the guideline-mandated quality of maintenance for acute coronary syndrome along with percutaneous coronary intervention. Despite the established effectiveness of double antiplatelet therapy, adverse ischemic events are still occur which has sparked the growth of novel, more potent antiplatelet agents. We focus on this comprehensive review on the latest progress in dental antiplatelet therapy, treading the tight rope of effectiveness versus bleeding hazard, the search to ascertain the best period of dual antiplatelet therapy and future of personalized antiplatelet therapy.
The critical roles played with platelets in thrombosis in web sites of vascular trauma supply a strong reason for blocking their role within the setting of coronary artery disorder. After adhesion at the site of coronary vascular trauma in the existence of shear force, platelets experience regeneration and discharge adenosine diphosphate (ADP) from dense granules and generate lactic acid in membrane phospholipids via the cyclooxygenase 1 (cox 1 )/thromboxane synthase pathway and thrombin throughout the coagulation pathway onto surface of activated platelets. The relative contributions of those pesky receptors to in-vivo thrombosis remain incompletely defined. P2Y12, TP, and also PAR1 are related to redundancy within their answers (indicating pathways). For that reason, targeting over these receptor pathways by dental agents is an increasingly attractive anti thrombotic plan for intense in addition to longterm avoidance of cardiovascular events in patients with CAD and it has been broadly researched in clinical trials.